The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We observed substantial variation in mutation type and frequency by geographical region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations.
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Abstract
The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We observed substantial variation in mutation type and frequency by geographical region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations.
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INTRODUCTION
Women who carry germline mutations in either BRCA1 [MIM# 113705] or BRCA2 [MIM# 600185] are at an increased risk of breast and ovarian cancers. Estimates of cancer risk associated with BRCA1 and BRCA2 mutations vary depending on the population studied. For mutations in BRCA1, the estimated average risk of breast and ovarian cancers ranges from 57 to 65% and 20 to 50%, respectively (Chen & Parmigiani, 2007; Kuchenbaecker et al., 2017) . For BRCA2, average risk estimates range from 35 to 57% and 5 to 23%, respectively (Chen & Parmigiani, 2007; Kuchenbaecker et al., 2017) . Mutation-specific cancer risks have been reported that suggest breast cancer cluster regions (BCCR) and ovarian cancer cluster regions (OCCR) exist in both BRCA1 and BRCA2 Kuchenbaecker et al., 2017; Rebbeck et al., 2015) . The identification of mutations in BRCA1 or BRCA2 has important clinical implications, as knowledge of their presence is important for risk assessment and informs medical management for patients. Interventions, such as risk-reducing bilateral mastectomy and salpingo-oophorectomy or annual breast magnetic resonance imaging (MRI) screening, are available to women who carry deleterious BRCA1 or BRCA2 mutations to enable early detection of breast cancer and for active risk reduction by risk-reducing surgery (Domchek et al., 2010; Rebbeck et al., 2002; Saslow et al., 2007) .
The presence of BRCA1 or BRCA2 mutations can also influence cancer treatment decisions, principally around the use of platinum agents or poly(ADP-ribose) polymerase (PARP) inhibitors (Lord & Ashworth, 2017) or contralateral risk-reducing mastectomy. Increased numbers of women are having clinical genetic testing for BRCA1 and BRCA2 mutations, and recommendations continue to expand to whom testing should be offered (NCCN, 2017) .
In Whites drawn from the general populations in North America and the United Kingdom, the prevalence of BRCA1 and BRCA2 mutations has been estimated around a broad range from 0.1 to 0.3% and 0.1 to 0.7%, respectively (Peto et al., 1999; Struewing et al., 1997; Whittemore et al., 2004) . The Australian Lifepool study, studying a control population consisting of cancer-free women ascertained via population-based mammographic screening program, estimated the overall frequency of BRCA1 and BRCA2 mutations to be 0.65% (1:153), with BRCA1 mutations at 0.20% (1:500) and BRCA2 mutations at 0.45%
(1:222) (Thompson et al., 2016) . Estimates from the Exome Aggregation Consortium (ExAC) are similar, with frequencies of BRCA1 and BRCA2 mutations (excluding The Cancer Genome Atlas [TCGA] data) at 0.21% (1:480) and 0.31% (1:327), respectively; or combined at 0.51%
(1:195) (Maxwell, Domchek, Nathanson, & Robson, 2016) . As they do not include large genomic rearrangements, some newer populationbased estimates may still underrepresent the total number of BRCA1 and BRCA2 mutations. Although the overall prevalence of BRCA1 and BRCA2 mutations in most general populations is low, many hundreds of thousands of yet-to-be-tested individuals worldwide carry these mutations.
The prevalence of founder mutations in some racial/ethnic groups is much higher. For example, the mutations BRCA1 c.5266dup (5382insC), BRCA1 c.68_69del (185delAG) and BRCA2 c.5946del (6174delT) have a combined prevalence of 2-3% in U.S. Ashkenazi Jews (Roa, Boyd, Volcik, & Richards, 1996; Struewing et al., 1997; Whittemore et al., 2004) . For these mutations, double heterozygotes in BRCA1 and BRCA2 also have been reported (Friedman et al., 1998; Moslehi et al., 2000; Ramus et al., 1997a; Rebbeck et al., 2016) . Several other founder mutations have been identified, including the Icelandic founder mutation BRCA2 c.771_775del (999del5) (Thorlacius et al., 1996) , the French Canadian mutations BRCA1 c.4327C > T (C4446T), the BRCA2 c.8537_8538del (8765delAG) (Oros et al., 2006b; Tonin et al., 2001; Tonin, Mes-Masson, Narod, Ghadirian, & Provencher, 1999) , the BRCA1 mutations c.181T > G, and c.4034del in CentralEastern Europe (Gorski et al., 2000) , the BRCA1 c.548-?−4185+?del in Mexico (Villarreal-Garza et al., 2015b; Weitzel et al., 2013) , the BRCA2 mutation c.9097dup in Hungary (Ramus et al., 1997b; Van Der Looij, et al., 2000) , and others. These mutations represent the majority of mutations observed in these populations and have been confirmed as true founder mutations as they have common ancestral haplotypes (Neuhausen et al., , 1998 Oros et al., 2006a (Ferla et al., 2007) . Similarly, a number of recurrent mutations specific to non-European populations also have been reported in Hispanic/Mexican, African American, Middle Eastern, and Asian populations (Bu et al., 2016; Ferla et al., 2007; Kurian, 2010; Lang et al., 2017; Ossa & Torres, 2016; Villarreal-Garza et al., 2015b ).
The mutational spectra in BRCA1 and BRCA2 are best delineated in Whites from Europe and North America. However, data on mutational spectra in non-White populations of Asian, African, Mediterranean, South American and Mexican Hispanic descent have also been reported (Abugattas et al., 2015; Ahn et al., 2007; Alemar et al., 2016; Bu et al., 2016; Eachkoti et al., 2007; Ferla et al., 2007; Gao et al., 2000; Gonzalez-Hormazabal et al., 2011; Ho et al., 2000; Jara et al., 2006; John et al., 2007; Kurian, 2010; Laitman et al., 2011; Lang et al., 2017; Lee et al., 2003; Li, et al., 2006; Nanda et al., 2005; Ossa & Torres, 2016; Pal, Permuth-Wey, Holtje, & Sutphen, 2004; Rodríguez et al., 2012; Seong et al., 2009; Sharifah et al., 2010; Solano et al., 2017; Song et al., 2005; Song et al., 2006; Toh et al., 2008; Torres et al., 2007; Troudi et al., 2007; Villarreal-Garza et al., 2015b; Vogel et al., 2007; Weitzel et al., 2005; Weitzel et al., 2007; Zhang et al., 2009 ). In the current study, we provide a global description of BRCA1 and BRCA2 mutations by geography and race/ethnicity from the investigators of the Consortium of
Investigators of Modifiers of BRCA1/2 (CIMBA).

METHODS
Details of centers participating in CIMBA and data collection protocols have been reported previously (Antoniou et al., 2007) . Details of the CIMBA initiative and information about the participating centers can be found at http://cimba.ccge.medschl.cam.ac.uk/ (ChenevixTrench et al., 2007) . All included mutation carriers participated in clinical or research studies at the host institutions after providing informed consent under IRB-approved protocols. Sixty-nine centers and multicenter consortia submitted data that met the CIMBA inclusion criteria (Antoniou et al., 2007) . Only female carriers with pathogenic BRCA1 and/or BRCA2 mutations were included in the current analysis. One mutation carrier per family in the CIMBA database was included in this report. The actual family relationships (e.g., pedigrees)
were not available, but a variable that defined family membership supplied by each center was used for this purpose. Less than 1% of families (86 of 29,700) had two family members with two different mutations. In these situations, each mutation observed in the family was included in the analysis. In the case of the 94 dual mutation carriers (i.e., individuals with both BRCA1 and BRCA2 mutations), one of the two mutations was chosen at random for inclusion in the analysis.
The CIMBA data set was used to describe the distribution of mutations by effect and function. For the remaining analyses, mutations were excluded if self-reported race/ethnicity data were missing. Pathogenicity of mutation was defined as follows: (1) generating a premature termination codon (PTC), except variants generating a PTC after codon 1854 in BRCA1 and after codon 3309 of BRCA2, (2) large in-frame deletions that span one or more exons, and (3) deletion of transcription regulatory regions (promoter and/or first exon) expected to cause lack of expression of mutant allele. We also included missense variants considered pathogenic by using multifactorial likelihood approaches (Bernstein et al., 2006; Goldgar et al., 2004) . Mutations that did not meet the above criteria but have been classified as pathogenic by Myriad Genetics, Inc. (Salt Lake City, UT) also were included. Classification of nonsense-mediated decay (NMD) was based on in-silico predictions and was not based on molecular classification (Anczukow et al., 2008 This information may be periodically updated as new data become available. Table 1 presents a summary of the type of BRCA1 or BRCA2 mutations and their predicted effect on transcription and translation. The most common mutation type was frameshift followed by nonsense. The most common effect of BRCA1 and BRCA2 mutations was premature translation termination and most of the mutant mRNAs were predicted F I G U R E 1 Countries (in red) that provided data on BRCA1 and/or BRCA2 mutation carriers in this report. Race/ethnic breakdown is reported for countries with more than 100 observations with multiple ethnicities totaling at least 10% of the country's sample (i.e., Australia, Brazil, Canada, USA) to undergo nonsense-mediated mRNA decay (Anczukow et al., 2008) .
RESULTS
Mutations in BRCA1 and BRCA2
Mutation type and effect
Despite having the same spectrum of mutations in BRCA1 and BRCA2, the frequency distribution by mutation type, effect, or function differed significantly (p < .05) between BRCA1 and BRCA2 mutation carriers for many groups, as shown in Table 1 . These observed differences are largely because genomic rearrangements and missense mutations account for a much higher proportion of mutations in BRCA1 when compared with BRCA2, as previously described (Welcsh & King, 2001 ).
We and others have found that BCCR and OCCR exist that may confer differential cancer risks Gayther et al., 1995; Kuchenbaecker et al., 2017; Rebbeck et al., 2015) . Figure 2 reports the relative frequency of mutations in the BCCR and OCCR by race/ethnicity. Compared with Whites, we observed differences in the relative frequency of mutations in the BRCA1 BCCR and OCCR in Asians and Hispanics, and in the BRCA2 OCCR in Hispanics. To the degree that the mutations within the BCCRs and OCCRs conferred differential cancer risks, these data suggest that BRCA1 and BRCA2 mutation-associated cancer risks may vary by race/ethnicity.
Geography and race/ethnicity
The most common mutations by country are summarized in Table 2 (BRCA1) and Table 3 contributed fewer than 10 mutation carriers to the CIMBA database.
Many of these mutations were submitted to the central database by CIMBA centers that ascertained these patients, but these patients originated from a different country. Based on such small numbers, it was impossible to make inferences about the relative importance of mutations in these locations. A description of the major ethnicity by country is provided in Supporting Information Table S2 .
The mutational distribution among the major racial/ethnic groups and by geography is summarized in Tables 4 and 5. Table 4 includes only those individuals for whom self-identified race/ethnicity was recorded.
Note that in some countries it is prohibited to collect data on race and ethnicity, so this information is missing. Among the 10 most common BRCA1 mutations in each racial/ethnic group, a few were seen in sev- P-values reflect the comparison of frequencies between BRCA1 and BRCA2 mutation carriers. a References (Anczukow et al., 2008; Buisson, et al., 2006; Mikaelsdottir, et al., 2004; Perrin-Vidoz, et al., 2002; Ware, et al., 2006) only tested for the three founder mutations, this number is likely to be underestimated.
In African Americans, the majority of BRCA1 mutations were not observed in any other racial/ethnic group, implying these mutations may be of African origin. In Hispanics, the most common BRCA1 mutations also were observed among individuals from other regions who did not self-identify as Hispanic, including BRCA1 c.3331_3334del
(also observed in Australia, Europe, USA, and the UK), and BRCA1 c.68_69del (the Jewish founder mutation) (Weitzel et al., 2005 .
The BRCA1 c.815_824dup mutation has been reported as being of African origin, but has also been reported as a recurrent mutation in Mexican Americans, perhaps as a reflection of the complex continental admixture of this population (Villarreal-Garza et al., 2015b) . BRCA1
c.390C > A and c.5496_5506delinsA were most commonly found in the Asian population. In BRCA2, c.2808_2811del was found among the 10 most frequent mutations in all races/ethnicities.
Recurrent mutations
As expected, the most common mutations in the entire data set were the founder mutations BRCA1 c.5266dup (5382insC), BRCA1
c.68_69del (185delAG), and BRCA2 c.5946del (6174delT). In part, the F I G U R E 2 Proportion of mutations in the breast cancer cluster regions (BCCR) and ovarian cancer cluster region (OCCR) in BRCA1 and BRCA2 by ethnicity as defined previously (Rebbeck et al., 2015) . Asterisk indicates proportion is significantly different than Caucasian proportion (p-value < 0.05) high frequency of these mutations is a consequence of panels that facilitate testing for these three mutations in women of Jewish descent.
However, these two BRCA1 mutations also are relatively common in regions with a low proportion of individuals who self-identify as Jewish (e.g., Hungary, Czech Republic, France, Germany, Italy, Poland Spain, Russia, and UK). BRCA1 c.5266dup is a founder mutation thought to have originated 1800 years ago in Scandinavia/Northern Russia, entering the Ashkenazi-Jewish population 400-500 years ago, and thus has origins and a spread pattern independent of the Ashkenazim (Hamel et al., 2011) . Haplotype studies have been used to determine the origin of BRCA1 c.68_69del in populations not considered to have a high proportion of Jewish ancestry. In some populations, such as the Hispanics in the USA and Latin American, it is associated with the Ashkenazi Jewish haplotype, presumably due to unrecognized (Jewish) ancestry (Ah Mew, Hamel, Galvez, Al-Saffar, & Foulkes, 2002; Velez et al., 2012; Weitzel et al., 2005) . In other populations, such as Pakistani and Malaysians, where BRCA1 c.68_69del is a recurrent mutation, it appears to have arisen independently, as it is carried on a distinct haplotype (Kadalmani et al., 2007; Rashid et al., 2006) . A different haplotype was also reported for several British families (the 'Yorkshire haplotype') that is distinct from both the Jewish and the Indian-Pakistani haplotypes (Laitman et al., 2013; Neuhausen et al., 1996) .
The only locations in which these three founder mutations were not commonly observed were Belgium and Iceland. Iceland has another founder mutation (i.e., BRCA2 c.771_775del). Yet other founder mutations included BRCA1 c.4327C > T and BRCA2 c.8537_8538del in
Quebec. This latter mutation in BRCA2 also is the most common mutation in high-risk families in Sardinia (Pisano et al., 2000) and was also reported in a few Jewish Yemenite families, with a distinct haplotype (Palomba et al., 2007) . The BRCA1 c.181T > G mutation was observed in Central Europe (Austria, Czech Republic, Germany, Hungary, Italy and Poland), but also observed in the US, Argentina, Latvia, Lithuania and Israel. This mutation has been found on a common haplotype in individuals of Polish and Ashkenazi Jewish ancestry, suggesting it is an Eastern European founder mutation (Kaufman, Laitman, Gronwald, Lubinski, & Friedman, 2009) . The large rearrangement mutation in BRCA1 c.548-?_4185+?del (ex9-12del) appears to be an important founder mutation in Mexico, with findings of a common haplotype and an estimated age at 74 generations (∼1,500 years) ).
We observed a number of other recurrent mutations. BRCA1 c.3331_3334del comprised more than half of all mutations identified in Colombia, consistent with a previous report that this is a founder mutation in the Colombian population (Torres et al., 2007) . However, this mutation has not been found at high rates in a second Colombian population (Cock-Rada, et al., 2017) . >T (18) c.5266dup (7) c.1374del (4) c.68_69del (4) c.3228_3229del ( c.5496_5506delinsA (17) c.922_924delinsT (11) c.5030_5033del (9) c.3627dup ( (135) c.4035del (11) c.68_69del (7) c.5026_5027del (1) c.4185+2T
c.68_69del (62) c.5123C > A (61) c.3770_3771del (23) c.3331_3334del ( (14) c.1389_1390del (9) c.3847_3848del (7) Czech Republic. c.6275_6276del (1) c.2224C > T (1) c.5542del (1) c.6502G > T (1) F I G U R E 3 BRCA1 mutation distribution in African American, Asian, and Hispanic. Length of mutation indicator reflects the number of observed mutations. Domains are zinc/ring finger (green); BRCT domain (red); BRCT (C terminus) (blue). Mutation type is indicated for each mutation by color: green: missense mutations; black: truncating mutations (nonsense, nonstop, frameshift deletion, frameshift insertion, splice site, in-frame mutations); purple: all other types of mutations generations ago. However, due to the diversity of the haplotypes, multiple independent origins could not be ruled out (Neuhausen et al., 1998) . BRCA2 c.6275_6276del was a recurrent BRCA2 mutation in Australia, the UK, Belgium, Spain, the Netherlands, and North America.
This mutation has been estimated to have originated 52 (24-98) generations ago from a single founder (Neuhausen et al., 1998) . Recurrent or founder mutations were observed in diverse populations. For example, the c.115T > G (Cys39Gly) mutation has been described in Greenlanders (Hansen et al., 2009 ). The c.2641G>T and c.7934del mutations have both been reported as founder mutation in South African
Afrikaners (Reeves et al., 2004) .
DISCUSSION
We have reported worldwide distribution of BRCA1 and BRCA2 muta- and BRCA2 mutation screening are not available. However, mutations that are in a specific population and that capture a sufficient Before such panels can be developed, population-based studies of mutation frequency in specific populations should be undertaken. The data reported herein provide a list of the recurrent mutations around which such panels could be developed, but the frequencies are not population based, particularly in settings where founder mutations are preferentially screened (e.g., the Jewish founder panels). Similarly, putative founder mutations identified by assessing common ancestral origins of specific mutations (rather than just high prevalence; Table 5) may form the basis of population-specific BRCA1 and BRCA2 mutation screening panels.
We report the distribution of BRCA1 and BRCA2 mutations in nearly 30,000 families of bona-fide disease-associated mutations. The strengths of this report include the large sample size that reflects a geographically and racially/ethnically diverse set of BRCA1 and BRCA2 mutation carriers. However, some limitations need to be considered.
First, the sample set presented here does not reflect a systematic study of these populations or races/ethnicities; the data reflect patterns of recruitment (e.g., individuals with higher risk or prior diagnosis of cancer who consented to participate in research protocols) that contributed to the CIMBA consortium. Certain racial/ethnic or sociodemographic groups are under-or overrepresented or missing in our data set and, as a consequence, mutations may be over-or underrepresented. For example, the existence of a commercial panel of three Jewish founder mutations enhances genetic testing for those mutations. As a result, the most frequently observed mutations in some populations c.5503C Third, we presented the mutations in terms of type or effect ( Hungarian ancestry (Ramus et al., 1997b; van der Looij et al., 2000) .
In Iceland, only two mutations were reported: the founder mutation BRCA2 c.771_775del and the rarer BRCA1 c.5074G > A (Bergthorsson et al., 1998) . A number of other situations can be identified in which specific mutations explain a large proportion of the total mutations observed in a population. These and other such examples suggest that targeted mutation testing panels that include specific mutations could be developed for use in specific populations. Finally, we focused on female BRCA1 and BRCA2 mutation carriers in this report. However, the growing knowledge about BRCA1 and BRCA2-associated cancers in men, particularly prostate cancer (Ostrander & Udler, 2008; Pritchard et al., 2016) , suggests that the information presented herein will also have value in genetic testing of men. 
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